# Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

> **NCT07637851** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 43 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Ubamatamab
- **DRUG:** Chemotherapy
- **DRUG:** Bevacizumab
- **DRUG:** GCSF

## Key facts

- **NCT ID:** NCT07637851
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-09
- **Final completion:** 2030-04
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07637851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07637851, "Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07637851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*